Citius Pharmaceuticals Inc (CTXR) 0.6400 $CTXR
Post# of 273242
Posted On: 09/20/2016 9:10:08 PM
Citius Pharmaceuticals Inc (CTXR) 0.6400 $CTXR
Citius Pharmaceuticals to Present at the 2016 Aegis Growth Conference
PR Newswire - Mon Sep 19, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its President and CEO, Myron Holubiak, will present at the 2016 Aegis Growth Conference. The Conference will be held on September 20-22, 2016 at the Encore at Wynn Las Vegas.
Citius Initiates Mino-Lok(TM) Phase 3 Trial
PR Newswire - Tue Sep 13, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius" (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated the pivotal Phase 3 clinical trial Mino-Lok(TM), an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).
MEDP: 30.44 (-0.13)
Citius Pharmaceuticals, Inc., Initiates Manufacturing of Mino-Lok(TM)
PR Newswire - Thu Sep 08, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius" (OTC QB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated manufacturing for the company's clinical trial of Mino-Lok (TM), an antibiotic lock solution used to salvage central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).
Citius Pharmaceuticals to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Wed Sep 07, 9:32AM CDT
Citius Pharmaceuticals, Inc. ("Citius" (OTC QB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Chairman, Len Mazur, will present at the Rodman & Renshaw 18th Annual Global Investment Conference. The Conference will be held on September 11-13, 2016 at the Lotte New York Palace Hotel, New York City.
Citius Announces Completion of In-Depth Interviews on Patient-Reported Outcomes: Signs and Symptoms of Hemorrhoids and Treatments
CNW Group - Tue Aug 23, 12:55PM CDT
Leading Life Sciences Market Research Firm Conducted Patient Interviews
Looking for "Firsts" in Health Care? Check Out Upcoming Catalysts for Citius Pharmaceuticals
PR Newswire - Thu Aug 04, 9:13AM CDT
By Sara Bowman, Senior Staff Writer, Online Media Group, Inc.
Citius Pharmaceuticals Provides Shareholder Update on Recent Achievements
PR Newswire - Mon Aug 01, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius" (OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, today provided shareholders with an update regarding the company's recent more notable achievements.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.90 (-0.10)
Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids
PR Newswire - Mon Feb 01, 6:00AM CST
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) today announced top line data from the first Phase 2a clinical trial of hydrocortisone acetate (HC) and lidocaine hydrochloride (L) as single agents and in combination (HC+L) in patients with grade I and II hemorrhoids. Citius' hydrocortisone and lidocaine cream is targeting to become the first FDA -approved prescription product to treat hemorrhoids in the U.S.
Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors
PR Newswire - Thu Oct 08, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company" announced today that it has appointed Mr. Suren Dutia to the board of directors effective October 8, 2015.
Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors
PR Newswire - Tue Oct 06, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company" announced today that it has appointed Mr. Myron Holubiak to the board of directors effective October 1, 2015.
BIOS: 2.87 (-0.05), ASMB: 7.32 (+0.16)
Citius Pharmaceuticals to Present at the 2016 Aegis Growth Conference
PR Newswire - Mon Sep 19, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its President and CEO, Myron Holubiak, will present at the 2016 Aegis Growth Conference. The Conference will be held on September 20-22, 2016 at the Encore at Wynn Las Vegas. Citius Initiates Mino-Lok(TM) Phase 3 Trial
PR Newswire - Tue Sep 13, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated the pivotal Phase 3 clinical trial Mino-Lok(TM), an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). MEDP: 30.44 (-0.13)
Citius Pharmaceuticals, Inc., Initiates Manufacturing of Mino-Lok(TM)
PR Newswire - Thu Sep 08, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC QB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated manufacturing for the company's clinical trial of Mino-Lok (TM), an antibiotic lock solution used to salvage central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). Citius Pharmaceuticals to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Wed Sep 07, 9:32AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC QB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Chairman, Len Mazur, will present at the Rodman & Renshaw 18th Annual Global Investment Conference. The Conference will be held on September 11-13, 2016 at the Lotte New York Palace Hotel, New York City. Citius Announces Completion of In-Depth Interviews on Patient-Reported Outcomes: Signs and Symptoms of Hemorrhoids and Treatments
CNW Group - Tue Aug 23, 12:55PM CDT
Leading Life Sciences Market Research Firm Conducted Patient Interviews
Looking for "Firsts" in Health Care? Check Out Upcoming Catalysts for Citius Pharmaceuticals
PR Newswire - Thu Aug 04, 9:13AM CDT
By Sara Bowman, Senior Staff Writer, Online Media Group, Inc.
Citius Pharmaceuticals Provides Shareholder Update on Recent Achievements
PR Newswire - Mon Aug 01, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, today provided shareholders with an update regarding the company's recent more notable achievements. OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.90 (-0.10)
Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids
PR Newswire - Mon Feb 01, 6:00AM CST
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) today announced top line data from the first Phase 2a clinical trial of hydrocortisone acetate (HC) and lidocaine hydrochloride (L) as single agents and in combination (HC+L) in patients with grade I and II hemorrhoids. Citius' hydrocortisone and lidocaine cream is targeting to become the first FDA -approved prescription product to treat hemorrhoids in the U.S.
Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors
PR Newswire - Thu Oct 08, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company"
announced today that it has appointed Mr. Suren Dutia to the board of directors effective October 8, 2015. Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors
PR Newswire - Tue Oct 06, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company"
announced today that it has appointed Mr. Myron Holubiak to the board of directors effective October 1, 2015. BIOS: 2.87 (-0.05), ASMB: 7.32 (+0.16)
(0)
(0)Scroll down for more posts ▼